"Given the high level of uncertainty with NKTR
's clinical stage drugs and its lack of current cash flow, however, we continue to recommend a Hold," Scarola wrote.
Tickers featured: ADA, ALKS, AMLN, CEPH, FRX, IP, JNJ, LLY, MNKD, MNTA, NEOL, NKTR
, NSTK, PG.
Nektar Therapeutics (NASDAQ: NKTR
) reported revenues of $23.3 million, down sharply from $1.088 billion last year.
ALSO LOWER: Nektar (NKTR
), down 37% after management disclosed that the scope of collaboration with partner Bristol-Myers (BMY) is now narrowed and that there were some issues pertaining to the manufacturing of bempegaldesleukin that potentially led to the drastic difference in response rate between the November 2017 and June 2018 data announcement of the Phase II PIVOT-02 results...
Tickers featured: ABGX, AMGN, ANDS, ARIA, AVII, BIIB, BMY, CBST, CELG, CEPH, CHIR, DNA, ENCY, ENZN, G, GENZ, GILD, GSK, GTXI, IDIX, IMCL, INHX, JNJ, MDCO, MOGN, MRK, NBIX, NKTR
, NVS, ONXX, PA-, PANC, PFE, PHRM, RHHVF, S, SEPR, SGP, SNY, SUPG, TEVA/IVX, UTHR, VRTX.
* Mizuho lowered the price target for Nektar Therapeutics(NASDAQ: NKTR
) from $79 to $21.
- San Francisco, California-based research-based development stage biopharmaceutical company Nektar Therapeutics (NASDAQ: NKTR
) has presented new clinical and preclinical data for NKTR-181 at the Annual Scientific Meeting of the College on Problems of Drug Dependence, the company said.
Tickers featured: ABCO, AGN, AVID, BFT, GTRC, HANS, IMDC, KO, LTM, MRX, NKTR
, PAMAX, PEP, PFE, SEPR, WGO.
For real-time updates on NKTR
, beat the news and login or try Benzinga Pro.
Nektar Therapeutics (NKTR
) and Bristol-Myers Squibb (BMY) announced that the FDA has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin, NKTR-214, in combination with Bristol-Myers Squibb's Opdivo for the treatment of patients with previously untreated unresectable or metastatic melanoma.
- Waltham, Massachusetts-based clinical stage biopharmaceutical company Syndax Pharmaceuticals (NASDAQ: SNDX) and San Francisco, California-based biopharmaceutical company Nektar Therapeutics (NASDAQ: NKTR
) have formed a non-exclusive, clinical collaboration to evaluate Nektar's NKTR-214 in combination with Syndax's entinostat, in patients with metastatic melanoma who have previously progressed on treatment with an anti-programmed death receptor-1 (PD-1) agent, the companies said.
Tickers featured: ALKS, ARDM, DRRX, EMIS, LLY, MNKD, NKTR
, NVO, PFE, SNY.